What differentiates ISPE events, from others organized by commercial event organizers, is the QUALITY of the content. The topics are discussed and prepared by colleagues - not by event organizers who have collected pharmaceutical “buzz words” and don’t truly understand our industry. Speakers at ISPE events are invited because they are close to the industry and can provide inside knowledge on regulatory developments, industry trends, and best practices. The first ISPE Clinical Supply Event I attended took place in Vienna in September 2006. Since receiving my “First Time Attendee” ribbon, I’ve learned a lot at ISPE events from solutions to challenges we are all facing, networking, and sharing my knowledge and expertise with attendees. For me it has been a great experience being a member of a group that is so engaged in the pharmaceutical industry and so eager to share their know-how and to help others improve and grow in their careers. Last year UCB, Belgium hosted the ISPE Clinical Trial Supply event. We had a great group of people enjoying the event, who were engaged with the speakers and working together during the hands-on workshop sessions.
I’m now receiving a “10 year” ribbon and can confidently say sharing knowledge, discussing challenges, and learning about solutions is becoming even more important with the changes happening to the pharmaceutical industry on a daily basis. We all are affected by new regulations and feel the economic pressure to implement innovative solutions and develop more efficient supply chains concepts. By attending the ISPE Europe Annual Conference, you’re opening a door to becoming a part of this dynamic community, to contribute and learn from the discussions, share experiences, and engage yourself in task teams or committee work. We look forward to see you at the ISPE Europe Annual Conference 7-9 March in Frankfurt and future ISPE events.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...
